KPV vs GHK-Cu: Two Tripeptides Compared
KPV and GHK-Cu are both three-amino-acid peptides, but they come from different molecules and answer different questions. KPV (lysine, proline, valine) is the anti-inflammatory tail of the hormone alpha-MSH and is studied mostly in gut inflammation models; GHK-Cu (glycine, histidine, lysine bound to copper) is a plasma peptide studied for collagen, skin and wound repair. Here is how they compare, what the research on each found, and why the KLOW Blend puts them in the same vial.
Findings
- KPV is amino acids 11 to 13 of alpha-MSH, the part reviewers credit with most of the hormone’s anti-inflammatory activity, without its pigmentary action (Brzoska et al., 2008).
- In two mouse colitis models, KPV sped recovery, restored body weight and reduced inflammatory infiltrates; in mice lacking a working melanocortin-1 receptor, it rescued every treated animal from death during colitis (2008).
- GHK was isolated from human serum in 1973, and its copper complex stimulated collagen synthesis in fibroblasts from concentrations as low as 10-12 to 10-11 M (1988).
- In a randomised, placebo-controlled trial in diabetic foot ulcers, topical GHK-Cu gel reached 98.5% median closure against 60.8% for vehicle (1994).
- KPV’s research axis is inflammation signalling; GHK-Cu’s is tissue building and remodelling. No study has compared them head to head.
What is KPV?
KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (alpha-MSH), a 13-amino-acid peptide cut from the larger precursor proopiomelanocortin. Alpha-MSH has broad anti-inflammatory effects in animal models of dermatitis, colitis, arthritis and airway inflammation, but its pigmentary effect limits its use. KPV keeps the anti-inflammatory effect and lacks the pigmentary action, which is why it was singled out as an alternative (Brzoska et al., Endocr Rev, 2008). An earlier review attributed most of alpha-MSH’s anti-inflammatory activity to this tripeptide (Luger and Brzoska, Ann Rheum Dis, 2007). Its origin is covered in Lysine, Proline, Valine: How KPV Comes From Alpha-MSH.
The gut inflammation research
KPV’s strongest data come from colitis models. In DSS colitis in mice, KPV led to earlier recovery, a significantly stronger regain of body weight, fewer inflammatory infiltrates and lower myeloperoxidase activity in colonic tissue; it also aided recovery in T-cell transfer colitis. In mice with a non-functional melanocortin-1 receptor, KPV rescued all treated animals from death during DSS colitis, which suggests the effect is at least partly independent of that receptor (Kannengiesser et al., Inflamm Bowel Dis, 2008).
The same year, a second group showed that KPV enters intestinal epithelial cells and T cells through PepT1, a di- and tripeptide transporter that is induced in the colon during inflammatory bowel disease. Nanomolar KPV inhibited NF-kappaB and MAP kinase signalling and reduced pro-inflammatory cytokine secretion, and KPV given in drinking water reduced DSS- and TNBS-induced colitis in mice (Dalmasso et al., Gastroenterology, 2008). Later work loaded KPV into hyaluronic acid-coated nanoparticles that delivered it to colonic epithelial cells and macrophages, accelerating mucosal healing in a mouse model of ulcerative colitis (Xiao et al., Mol Ther, 2017). Published human trials of KPV itself were not found. More is in KPV: The Anti-Inflammatory Tripeptide, Explained.
What is GHK-Cu?
GHK is glycyl-histidyl-lysine, first described in 1973 as a tripeptide in human serum that prolonged the survival of normal liver cells (Pickart and Thaler, Nat New Biol, 1973). It binds copper(II) tightly, and the copper complex is what gives the powder and solution their blue colour (why GHK-Cu is blue). Plasma GHK falls with age, from about 200 ng/mL at age 20 to 80 ng/mL by age 60 (Pickart and Margolina, Int J Mol Sci, 2018).
The collagen and wound research
GHK-Cu stimulated collagen synthesis in fibroblast cultures, starting between 10-12 and 10-11 M and peaking at 10-9 M, independent of any change in cell number. The authors noted a GHK sequence inside the alpha 2(I) chain of type I collagen, which suggests the peptide may be released by proteases at a wound (Maquart et al., FEBS Lett, 1988). A 2015 review describes GHK stimulating collagen, dermatan sulphate, chondroitin sulphate and decorin, modulating both metalloproteinases and their inhibitors, and attracting immune and endothelial cells to an injury; the authors report it can up- or downregulate at least 4,000 human genes (Pickart et al., Biomed Res Int, 2015).
The clearest human result is topical. In a multicentre, randomised, evaluator-blinded, placebo-controlled study in diabetic neuropathic foot ulcers, GHK-Cu gel produced 98.5% median closure against 60.8% for vehicle, closure was three times faster, and ulcer infections fell to 7% against 34% (Mulder et al., Wound Repair Regen, 1994). A small trial after laser resurfacing found higher patient satisfaction with GHK-Cu products but no objective difference in wrinkles or redness (Miller et al., Arch Facial Plast Surg, 2006). The wider literature is in GHK-Cu: The Skin Research.
How do KPV and GHK-Cu compare side by side?
| Question | KPV | GHK-Cu |
|---|---|---|
| What is it? | Lys-Pro-Val, alpha-MSH residues 11 to 13 | Gly-His-Lys bound to copper(II) |
| Size | 3 amino acids | 3 amino acids plus a copper ion |
| Main research area | Inflammation, especially colitis models | Collagen, skin and wound repair |
| Mechanism focus | PepT1 uptake; NF-kappaB and MAP kinase inhibition | Fibroblast collagen and matrix synthesis; gene expression |
| Human evidence | No published human trials found | Topical: diabetic ulcer trial, 1994 |
| Colour in solution | Clear | Blue |
| Forms we supply | 10 mg vial, nasal spray, in KLOW | 50 mg and 100 mg vials, nasal spray, in GLOW and KLOW |
Which one fits which research question?
- Inflammatory signalling, NF-kappaB, cytokine output and gut inflammation: KPV. Its literature is built on colitis models and on its uptake through PepT1.
- Collagen, extracellular matrix, skin ageing and wound closure: GHK-Cu, which has the fibroblast work and a controlled human wound trial.
- Wound-healing designs that track both inflammation and rebuilding: both. A 2025 review of tripeptides in wound care covers GHK-based formulations for fibroblast migration, collagen and elastin, and KPV-loaded hydrogels for reducing inflammation and supporting tissue regeneration (Adnan et al., Int J Med Sci, 2025).
Can KPV and GHK-Cu be studied together?
Yes. They act on different stages of repair: KPV on the inflammatory signal, GHK-Cu on matrix rebuilding. Both are tripeptides, so they sit together in solution without one dwarfing the other by size. No study of the pair as a combination was identified; the rationale comes from each peptide’s own literature.
The KLOW Blend combines 50 mg GHK-Cu and 10 mg KPV with 10 mg each of BPC-157 and TB-500 (what is KLOW). For separate control of each variable, the single vials are the better choice. The trade-offs are set out in GHK-Cu vs KLOW.
How are KPV and GHK-Cu supplied?
KPV comes as a 10 mg lyophilised vial and a ready-mixed KPV Nasal Spray; GHK-Cu as 50 mg and 100 mg vials and a ready-mixed GHK-Cu Nasal Spray. The sprays are metered at 0.175 mL per press. Vials are reconstituted with bacteriostatic water (see the KPV and GHK-Cu reconstitution guides), and storage is covered in how long KPV lasts and how long GHK-Cu lasts. Certificates of analysis are on the lab reports page, and every order ships from within Canada.
KPV and GHK-Cu are supplied for laboratory research use only. The studies above were cell, animal and clinical research using their own preparations.
Frequently asked questions
What is the difference between KPV and GHK-Cu?
KPV is lysine-proline-valine, the anti-inflammatory end of alpha-MSH, studied mostly in colitis models. GHK-Cu is glycine-histidine-lysine bound to copper, a plasma peptide studied for collagen synthesis, skin and wound repair.
Is KPV a copper peptide?
No. KPV carries no metal and is clear in solution. GHK-Cu is the copper peptide, and its bound copper(II) is what makes it blue.
Is GHK-Cu stronger than KPV?
The two have not been compared head to head, and they are studied for different things: KPV for inflammatory signalling, GHK-Cu for matrix and wound repair. GHK-Cu has a controlled human wound trial; KPV’s data are from cell and animal models.
Can KPV and GHK-Cu be studied together?
Yes. They act on different stages of repair, and the KLOW Blend combines 50 mg GHK-Cu and 10 mg KPV with BPC-157 and TB-500 in one vial. No study of the pair as a combination was identified.
Where can I buy KPV and GHK-Cu in Canada?
Vistara Labs supplies KPV as a 10 mg vial and nasal spray and GHK-Cu as 50 mg and 100 mg vials and a nasal spray, shipped from within Canada by Canada Post Xpresspost.
Product details from vistaralabs.ca, October 2026. Sources: Brzoska T et al. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008. PMID 18612139. Luger TA, Brzoska T. alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Ann Rheum Dis. 2007. PMID 17934097. Kannengiesser K et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008. PMID 18092346. Dalmasso G et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008. PMID 18061177. Xiao B et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Mol Ther. 2017. PMID 28143741. Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nat New Biol. 1973. PMID 4349963. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018. PMID 29986520. Maquart FX et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988. PMID 3169264. Pickart L et al. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015. PMID 26236730. Mulder GD et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. Wound Repair Regen. 1994. PMID 17147644. Miller TR et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006. PMID 16847171. Adnan SB et al. Exploring the role of tripeptides in wound healing and skin regeneration: a comprehensive review. Int J Med Sci. 2025. PMID 41209547.
More on this: Peptides for Skin: What the Research Shows.
All products supplied by Vistara Labs are intended for laboratory research use only. They are not drugs, are not approved for human or veterinary use, and are not intended to diagnose, treat, cure or prevent any condition. Nothing on this page constitutes medical advice or guidance for use in humans.
